- NanoBone® is a next-generation osteoinductive bone graft
consisting of patented nanostructured hydroxyapatite for
remodelling bone
- Biocomposites to introduce NanoBone at the British
Orthopaedic Association's Annual Congress in Birmingham
KEELE, England, Sept. 12,
2024 /PRNewswire/ -- Biocomposites, an international
medical devices company that engineers, manufactures and markets
world leading products for regenerating bone and managing infection
in bone and soft tissue, today announces that it will begin
distributing its NanoBone range of products in the UK. The range
consists of NanoBone SBX Putty and NanoBone QD, which are next
generation synthetic bone grafts that provide reliable early
osteogenesis and bone formation.
The launch in the UK coincides with Biocomposites' attendance at
the British Orthopaedic Association's Annual Congress 2024, to be
held from 17-20 September 2024 at The
International Convention Centre in Birmingham. Biocomposites is a Platinum
Sponsor of this year's BOA congress, where staff will be hosting
Stand #17.
NanoBone's patented technology consists of nanostructured
hydroxyapatite embedded in a silica gel matrix, which is suspended
in a hydrogel/polymer silica carrier. This formulation provides the
fullest support for bone regeneration - providing comparable
healing rate to autograft and osteoinductive properties, but
without the costs and complications of harvesting. NanoBone is
preloaded and ready-to-use in a wide variety of applications to
maximise flexibility and efficiency during procedures.
NanoBone is manufactured by Biocomposites GmbH, a specialist
manufacturer of innovative bone graft substitutes for use in
orthopaedics, spine, foot and ankle, and dentistry, which
Biocomposites bought last year.
Following the acquisition, Biocomposites has successfully
integrated and developed the NanoBone range, aiming to serve a
greater number of surgeons and patients through its established,
global distribution network.
Dr. Walter Gerike, Managing
Director of Biocomposites GmbH, said: "NanoBone is a proven
technology that has already helped over 100,000 patients throughout
the world. The UK is a significant market and we are very pleased
to start selling our innovative range of ready-to-use products
there. This development furthers Biocomposites' position as the
go-to provider for surgeons requiring advanced bone regeneration
materials."
About Biocomposites
Biocomposites is an international medical device company that
engineers, manufactures and markets world leading products for use
in infection management in bone and soft tissue. Based in Keele,
UK, it has global operations across Europe, South
America, USA, Canada, China
and India. Biocomposites is a
world leader in the development of innovative calcium compounds for
surgical use. Its products regenerate bone and target infection
risks across a variety of specialties, including musculoskeletal
infection, orthopaedics, trauma, spine, foot and ankle, podiatry
and sports injuries. Biocomposites products are now used in over 1
million procedures per annum and sold in more than 100 countries
around the world. Please visit biocomposites.com to learn more.
View original
content:https://www.prnewswire.com/news-releases/biocomposites-to-distribute-its-nanobone-product-range-in-the-uk-302245506.html
SOURCE Biocomposites